Is there a minimum age for cosentyx use?

Who can use Cosentyx?

The U.S. Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions [1]. However, before starting Cosentyx, there are certain factors to consider regarding age.

Is there a minimum age for Cosentyx use?

Cosentyx is approved for use in patients 6 years of age and older for psoriasis treatment, and for patients 2 years and older for psoriatic arthritis treatment [1].

For pediatric patients, the safety and efficacy of Cosentyx have been established in clinical trials involving children from birth to 17 years of age [2]. In these trials, the efficacy of Cosentyx was evaluated in children with moderate to severe plaque psoriasis [3].

Important considerations for pediatric use

When it comes to the use of Cosentyx in children, healthcare providers should carefully weigh the potential benefits and risks of treatment, especially since long-term effects of the drug on growth, puberty, and fertility in children are not well understood [2].

Parents or guardians should discuss their child's use of Cosentyx with their healthcare provider and carefully read the patient information, which includes important safety information about potential side effects, including infection, allergic reactions, injection site reactions, and depression [4].

References

[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation.

[2] Cosentyx in Pediatric Patients. Novartis Pharmaceuticals Corporation.

[3] Secukinumab in Pediatric Patients with Plaque Psoriasis. ClinicalTrials.gov.

[4] Cosentyx Patient Information. Novartis Pharmaceuticals Corporation.

Sources:

* [1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation.
* [2] Cosentyx in Pediatric Patients. Novartis Pharmaceuticals Corporation.
* [3] Secukinumab in Pediatric Patients with Plaque Psoriasis. ClinicalTrials.gov.
* [4] Cosentyx Patient Information. Novartis Pharmaceuticals Corporation.
* DrugPatentWatch.com – A comprehensive database on pharmaceutical patents (visit https://www.drugpatentwatch.com/).

Note: The safety and efficacy of Cosentyx in pediatric patients have been established in clinical trials, but parents or guardians should discuss the use of Cosentyx with their healthcare provider for personalized advice.